Harmony Biosciences resumed with an Outperform at Raymond James

Raymond James resumed coverage of Harmony Biosciences with an Outperform rating and $40 price target The Citizen Petition was dismissed, removing an overhang on the stock, and the firm sees upside opportunities along with the recent Wakix label expansion into pediatrics, and the upcoming Idiopathic Hypersomnia filing, the analyst tells investors in a research note. Raymond James adds that the outlook for Wakix sales remains strong, and the company continues to advance the recently expanded clinical pipeline.